Protein kinase inhibitor

Apollomics, Inc. Receives China Investigational New Drug Approval for APL-102 to Initiate a Phase 1 Study

Dr. Guoliang Yu, the companys Co-Founder, Chairman and CEO said that: APL-102 is a small molecule multi-kinase inhibitor developed by us.

Key Points: 
  • Dr. Guoliang Yu, the companys Co-Founder, Chairman and CEO said that: APL-102 is a small molecule multi-kinase inhibitor developed by us.
  • APL-102 may not only be used as a single agent to treat patients, but also has a potential of being co-administered with immunotherapy and other treatments as a combination therapy.
  • APL-102 is an oral, multi kinase inhibitor (mKi) targeting several key oncogenic drivers.
  • Apollomics owns the global clinical development, production and commercial sales rights of APL-102.

Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, November 5, 2020

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations that has been previously treated with an EGFR targeted tyrosine kinase inhibitor (TKI).

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations that has been previously treated with an EGFR targeted tyrosine kinase inhibitor (TKI).
  • The Phase II SUMMIT basket trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating EGFR exon 18 or HER2 mutations.
  • In the EGFR exon 18 mutation cohort, patients with lung cancer with single or complex EGFR exon 18 mutations, who were EGFR TKI nave or were previously exposed to EGFR TKI, were enrolled into this study and received 240 mg of neratinib daily as a single agent.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.

Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor

Retrieved on: 
Friday, October 9, 2020

XL092 is a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in cancers growth and spread.

Key Points: 
  • XL092 is a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in cancers growth and spread.
  • In designing XL092, Exelixis sought to build upon the experience and target profile of cabozantinib, the companys flagship medicine, while improving key characteristics, including clinical half-life.
  • Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors

Retrieved on: 
Friday, September 25, 2020

AYVAKYT demonstrated deep and durable clinical activity and was generally well-tolerated in patients with PDGFRA D842V mutant GIST with or without prior therapy.

Key Points: 
  • AYVAKYT demonstrated deep and durable clinical activity and was generally well-tolerated in patients with PDGFRA D842V mutant GIST with or without prior therapy.
  • GIST is a genomically driven sarcoma of the gastrointestinal (GI) tract, with PDGFRA D842V mutations implicated in a rare subset of patients.
  • As part of the conditional marketing authorization, Blueprint Medicines plans to conduct an observational, long-term study in patients with PDGFRA D842V mutant GIST treated with AYVAKYT.
  • AYVAKYT (avapritinib) is a kinase inhibitor approved in the EU for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial

Retrieved on: 
Saturday, September 19, 2020

Cabometyx in combination with Opdivo was associated with a longer duration of response than sunitinib, with a median duration of 20.2 months versus 11.5 months.

Key Points: 
  • Cabometyx in combination with Opdivo was associated with a longer duration of response than sunitinib, with a median duration of 20.2 months versus 11.5 months.
  • All these key efficacy results were consistent across the pre-specified International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk and PD-L1 subgroups.
  • The CheckMate -9ER data demonstrate meaningful efficacy benefits with nivolumab plus cabozantinib, which significantly improved overall survival and doubled progression-free survival and objective response rate with consistent effects observed across pre-specified subgroups.
  • Cabometyx in combination with Opdivo was well tolerated and reflected the known safety profiles of the immunotherapy and tyrosine kinase inhibitor components in previously untreated advanced RCC.

BerGenBio to Present At Sachs annual biotech In europe forum

Retrieved on: 
Friday, September 18, 2020

BERGEN, Norway, Sept. 18, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that CEO Richard Godfrey will be presenting at the Sachs Annual Biotech in Europe Forum.

Key Points: 
  • BERGEN, Norway, Sept. 18, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that CEO Richard Godfrey will be presenting at the Sachs Annual Biotech in Europe Forum.
  • Register for the event here: https://www.sachsforum.com/20bef-registration.html
    The presentation will be made available on the Company website in the Presentations section on the day.
  • AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases.
  • In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications.

$64.9 Billion Kinase Inhibitors Market - Global Outlook to 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 16, 2020

The "Kinase Inhibitors - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Kinase Inhibitors - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Kinase Inhibitors market accounted for $40.41 billion in 2019 and is expected to reach $64.90 billion by 2027 growing at a CAGR of 6.1% during the forecast period.
  • Some of the key factors propelling market growth include rise in awareness about kinase inhibitors, surge in product approvals, increase in incident of cancer diseases, and increase in investment from pharmaceutical companies.
  • In addition, increase in adoption of kinase inhibitors for newer applications, and emerging economies such as China, India and others, will create new opportunities for global kinase inhibitors market.

Kinnate Biopharma Appoints Dean J. Mitchell as Chairman of the Board

Retrieved on: 
Wednesday, September 9, 2020

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced the appointment of Dean J. Mitchell as board Chairman.

Key Points: 
  • Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced the appointment of Dean J. Mitchell as board Chairman.
  • On behalf of the entire Kinnate team, we are honored to welcome these world-class leaders to our board.
  • Mr. Mitchell currently serves on the Theravance Biopharma, ImmunoGen and Precigen (previously Intrexon) boards of directors.
  • Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers.

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

Retrieved on: 
Wednesday, September 2, 2020

The GEOMETRY mono-1 study results published in The New England Journal of Medicine further highlight the clinical benefit that Tabrecta can provide to patients with metastatic METex14 NSCLC, said Steven Stein, M.D., Chief Medical Officer, Incyte.

Key Points: 
  • The GEOMETRY mono-1 study results published in The New England Journal of Medicine further highlight the clinical benefit that Tabrecta can provide to patients with metastatic METex14 NSCLC, said Steven Stein, M.D., Chief Medical Officer, Incyte.
  • Incyte is eligible for a total of over $500 million in milestones as well as royalties of between 12-14% on global net sales by Novartis.
  • Tabrecta (capmatinib) is a kinase inhibitor that targets MET discovered by Incyte and licensed to Novartis in 2009.
  • Under the terms of the Agreement, Incyte granted Novartis exclusive worldwide development and commercialization rights to capmatinib and certain back-up compounds in all indications.

Kinnate Biopharma Closes $98 Million Series C Financing

Retrieved on: 
Wednesday, August 26, 2020

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced that it has raised $98 million in a Series C financing.

Key Points: 
  • Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced that it has raised $98 million in a Series C financing.
  • In December 2019, Kinnate closed a $74.5 million Series B financing.
  • Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers.
  • Headquartered in San Diego, the Kinnate team is composed of drug discovery experts supported by world-class scientific advisors and investors.